Bradycardia medical therapy: Difference between revisions

Jump to navigation Jump to search
ShiSheng (talk | contribs)
No edit summary
ShiSheng (talk | contribs)
Line 23: Line 23:
|MedCond = Persistently severe bradycardia|Acebutolol}}
|MedCond = Persistently severe bradycardia|Acebutolol}}
{{MedCondContrAbs
{{MedCondContrAbs
|MedCond = Symptomatic bradycardia (except in patients with a functioning artificial pacemaker)|Adenosine}}
|MedCond = Symptomatic bradycardia (except in patients with a functioning artificial pacemaker)|Adenosine}}



Revision as of 20:13, 5 September 2014

Bradycardia Microchapters

Home

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Bradycardia from other Conditions

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

Echocardiography

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Bradycardia medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Bradycardia medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Bradycardia medical therapy

CDC on Bradycardia medical therapy

Bradycardia medical therapy in the news

Blogs on Bradycardia medical therapy

Directions to Hospitals Treating Bradycardia

Risk calculators and risk factors for Bradycardia medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: M.Umer Tariq [2]

Overview

Medical Therapy

Urgent Treatment

  • Check drug list and remove drugs predisposing to bradycardia like beta blockers, calcium channel blocker, anti-arrhythmic drug.
  • Drug treatment for bradycardia is typically not indicated for patients who are asymptomatic.
  • In symptomatic patients, underlying electrolyte or acid-base disorders or hypoxia should be corrected first.
  • IV atropine may provide temporary improvement in symptomatic patients, although its use should be balanced by an appreciation of the increase in myocardial oxygen demand this agent causes. Atropine 0.5-1 mg IV or ET q3-5min up to 3 mg total (0.04 mg/kg)

Chronic Management

There are two main reasons for treating brandycardia:

  1. With bradycardia, the first is to address the associated symptoms, such as fatigue, limitations on how much an individual can physically exert, fainting (syncope), dizziness or lightheadedness, or other vague and non-specific symptoms.
  2. The other reason to treat bradycardia is if the person's ultimate outcome (prognosis) will be changed or impacted by the bradycardia.

Treatment in this vein depends on whether any symptoms are present, and what the underlying cause is. Primary or idiopathic bradycardia is treated symptomatically if it is significant, and the underlying cause is treated if the bradycardia is secondary.

Contraindicated medications

Persistently severe bradycardia is considered an absolute contraindication to the use of the following medications:

Symptomatic bradycardia (except in patients with a functioning artificial pacemaker) is considered an absolute contraindication to the use of the following medications:

References

Template:WH Template:WS